Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

This study has been terminated.
(no value in finding efficacy)
Sponsor:
Collaborators:
Merck Sharp & Dohme Corp.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT01174199
First received: July 30, 2010
Last updated: September 9, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: August 2016
  Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)